November 16, 2026
Source: drugdu
47

On November 10, 2026 (announced November 11), IASO Bio announced that the Investigational New Drug (IND) application for IASO208, a CD20-targeting in vivo CAR-T therapy developed on its proprietary InTelliCAR platform, was approved by China's National Medical Products Administration (NMPA), following the U.S. FDA's implicit clearance in September 2026. As the first lentiviral-vector-based in vivo CAR-T product from China to receive FDA IND clearance, IASO208 will build on Chinese investigator-initiated trial (IIT) data to initiate a Phase Ib study directly in the United States for adults with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
The China IND approval marks the formal entry of the InTelliCAR platform into synchronized U.S.–China clinical development and validates leveraging China's early clinical data to support global registrational development. IASO208 is the company's first product to obtain IND approval through China's 30-day expedited review pathway, demonstrating mature end-to-end capabilities across CMC, nonclinical studies, clinical trial design and communication with regulatory authorities.
IASO208 is being evaluated in an investigator-initiated, single-arm, open-label, dose-exploration study in patients with relapsed/refractory B-cell malignancies; patients require no conventional apheresis or lymphodepleting conditioning and receive a single intravenous infusion. To date, 11 patients have been dosed, with favorable tolerability and promising anti-tumor activity, and the early results have been selected for an Oral Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting (Abstract #705).
Founder, Chairperson and Chief Executive Officer Jinhua Zhang said the milestone moves the product from "U.S. IND approval" toward "synchronized U.S.–China clinical development." Founded in 2017, IASO Bio has a portfolio of ten products anchored by its core CAR-T therapy Equecabtagene Autoleucel (eque-cel), approved in China for relapsed/refractory multiple myeloma, and collaborates with partners including Innovent, Sana, Cabaletta and Umoja.
Source: https://enmobile.prnasia.com/releases/global/iaso-bio-announces-nmpa-ind-approval-for-iaso208-advancing-its-in-vivo-car-t-platform-into-synchronized-u-s-china-clinical-development-555802.shtml
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.